| [Download PDF]
|Year : 2007 | Volume
| Issue : 4 | Page : 354--357
Correlation between In vitro susceptibility and treatment outcome with azithromycin in gonorrhoea: A prospective study
P Khaki1, P Bhalla1, A Sharma1, V Kumar2,
1 Department of Microbiology, Maulana Azad Medical College, New Delhi - 110 002, India
2 Department of Dermatology, Venereology and Leprology, Lok Nayak Hospital, New Delhi - 110 002, India
Department of Microbiology, Maulana Azad Medical College, New Delhi - 110 002
Purpose: This prospective study was carried out to determine the antimicrobial susceptibility of Neisseria gonorrhoeae isolates by disc diffusion method and minimum inhibitory concentration (MIC) by E -test with special reference to azithromycin. Also, the correlation between in vitro susceptibility and treatment outcome with single 2 g oral dose azithromycin was assessed. Methods: The study included 75 gonococcal isolates from males with urethritis, females with endocervicitis and their sexual contacts. All isolates were subjected to susceptibility testing for penicillin, ciprofloxacin, tetracycline, ceftriaxone, spectinomycin, cefixime and azithromycin. Males with gonococcal urethritis were randomised to receive a single dose of either azithromycin or ceftriaxone. Forty-two men with urethritis received 2 g single oral dose azithromycin, while all other patients were given 250 mg parentral ceftriaxone. All patients were called for follow-up to assess clinical and microbiological cure rates. Results: While all the isolates were susceptible to ceftriaxone, spectinomycin, cefixime and azithromycin; 74 (98.7%), 24 (32%) and 23 (30.7%) strains were resistant to ciprofloxacin, penicillin and tetracycline respectively, by both disc diffusion method and E -test. The MIC range, MIC 50 and MIC 90 of N. gonorrhoeae strains, to azithromycin were 0.016-0.25, 0.064 and 0.19 mg/mL, respectively. Follow-up attendance of the patients was 52.4 with 100% clinical and microbiological cure rates. Conclusions: Results of our study indicate that 2 g single oral dose azithromycin is safe and effective in the treatment of uncomplicated gonorrhoea.
|How to cite this article:|
Khaki P, Bhalla P, Sharma A, Kumar V. Correlation between In vitro susceptibility and treatment outcome with azithromycin in gonorrhoea: A prospective study.Indian J Med Microbiol 2007;25:354-357
|How to cite this URL:|
Khaki P, Bhalla P, Sharma A, Kumar V. Correlation between In vitro susceptibility and treatment outcome with azithromycin in gonorrhoea: A prospective study. Indian J Med Microbiol [serial online] 2007 [cited 2020 May 29 ];25:354-357
Available from: http://www.ijmm.org/text.asp?2007/25/4/354/37338
The rapidly emerging antimicrobial resistance of Neisseria gonorrhoeae isolates to the currently recommended antibiotics, especially in areas where inefficient standard treatment regimens are applied, is a setback for effective treatment and control of gonococcal disease. ,, Sentinel surveillance of the in vitro antimicrobial susceptibility of clinical isolates of N. gonorrhoeae has a crucial role in preventing spread of resistant strains and monitoring effective antimicrobial therapy for gonorrhoea. ,
Although a successful outcome of antimicrobial therapy is conditioned by a number of factors, a good correlation between the level of in vitro susceptibility and the microbiological cure is essential for the prediction of treatment outcome. Strategies for the control of gonorrhoea have relied on the use of highly effective and, often, single-dose therapy administered at the time of diagnosis.  Due to the high prevalence of fluoroquinolone resistance in certain parts of India, , first line treatment with oral ciprofloxacin has been largely replaced by treatment with parenteral ceftriaxone. Another third-generation cephalosporin cefixime can be administered as an alternative oral therapy with efficacy being equivalent to that of ceftriaxone; , however, the association of higher cefixime minimum inhibitory concentrations (MICs) with chromosomally mediated penicillin resistance may suggest a slowly rising trend of chromosomally mediated cephalosporin resistance. 
There are a few reports, which have shown an in vitro activity of azithromycin against N. gonorrhoeae and also demonstrated the efficacy of a 1 or 2-g single dose of this agent for treatment of gonorrhoea. ,,,, Azithromycin has also been shown to have good activity against other sexually transmitted pathogens including Chlamydia trachomatis , Ureaplasma urealyticum and Haemophilus ducreyi . ,, There is hardly any data about comparison of in vitro susceptibility of N. gonorrhoeae isolates to azithromycin and clinical efficacy of azithromycin in treatment of gonorrhoea in India.
Therefore, this study was carried out to compare the results of disc diffusion method with MIC values by E -test for azithromycin and we also conducted a prospective study to assess the correlation between in vitro susceptibility and treatment outcome with azithromycin in gonorrhoea.
Materials and Methods
The study population comprised 77 males with urethritis, 22 females with endocervicitis and 10 their sexual contacts attending the STD clinic of Lok Nayak Hospital, New Delhi, between April 2005 and March 2006. All patients were included in the study after taking informed consent. A detailed history regarding demographic and clinical data was obtained from the patients. A full general physical and systemic examination was done before sample collection and treatment. Exclusion criteria were: antibiotic therapy with in the preceding four weeks, known hypersensitivity to macrolide antibiotic, serious cardiac, renal or hepatic disease, clinical evidence of disseminated gonococcal infection, other complications of gonorrhoeae or untreated syphilis and any condition that might affect gastro-intestinal absorption of antibiotics (e.g., peptic ulcer disease, gastrectomy).
Samples collection and processing
Urethral specimens from males and endocervical specimens from females were collected for preparation of smears and inoculation of selective modified Thayer-Martin agar. The specimens were transported to the laboratory at room temperature inside a candle jar with a candle lit inside within 1 hour. The smears prepared from discharge were stained by Gram stain and examined under oil immersion objective (1000×). Presumptive diagnosis of gonorrhoea was made on the basis of presence of gram-negative intracellular diplococci within polymorphonuclear leukocytes.
Treatment of patients
Treatment was assigned to males with gonococcal urethritis using consecutive randomization with a predetermined 2:1 azithromycin-to-ceftriaxone ratio. Patients were randomised to receive either azithromycin (2 g oral dose) or ceftriaxone (250 mg parentral). All patients were called for follow-up after 5-7 days to assess clinical response to treatment and to establish microbiological cure by collecting a repeat urethral or endocervical sample for direct microscopy and gonococcal culture. Occurrence of any adverse drug reaction was also recorded.
Isolation and identification of N. gonorrhoeae
The inoculated plates were incubated at 35-36 °C in a humid atmosphere (70% humidity) containing 3-7% carbon dioxide for 24-72 h. A humid environment was created by placing a moistened cotton wool ball at the bottom of the candle jar. N. gonorrhoeae was identified by colony morphology, Gram stain, oxidase reaction, superoxol test and rapid carbohydrate utilization test. Gonococcal isolates were stored at -70 °C in tryptic soy broth (Difco) containing 20% glycerol. 
Antimicrobial susceptibility testing
All the isolates were examined for susceptibility to penicillin (10 IU), ciprofloxacin (5 μg), tetracycline (30 μg), ceftriaxone (30 μg), spectinomycin (100 μg), cefixime (5 μg) and azithromycin (15 μg) by the agar disc diffusion method.  In addition, the MICs to all antibiotics except cefixime was determined by E -test. The E -test was performed as specified by the manufacturer (AB Biodisk). N. gonorrhoeae ATCC 49226 was included as quality control. The interpretative criteria for all antibiotics except azithromycin were as recommended by the Clinical and Laboratory Standards Institute (CLSI).  Criteria for interpretation of azithromycin was recommended by the Neisseria Reference Laboratory (NRL) at CDC.  β-Lactamase production was assayed using nitrocefin discs (BBL Cefinase; Becton Dickinson). 
Data management and statistical analyses were done using statistical software SPSS version 13.0. Chi-square test and Fisher's exact test were used to compare the responses to therapy. Linear regression analysis was carried out to correlate the MICs by E -test and inhibition zone diameters by disc diffusion method.
A total of 75 gonococcal strains were isolated from 67 (87%) out of 77 men with urethritis, 4 (18.2%) out of 22 women with endocervicitis and 4 (40%) out of 10 sexual contacts of these cases.
The antimicrobial susceptibilities of isolates are summarized in [Table 1],[Table 2]. All isolates were found to be susceptible to ceftriaxone, spectinomycin, cefixime and azithromycin. Seventy-four (98.7%), 24 (32%) and 23 (30.7%) strains were resistant to ciprofloxacin, penicillin and tetracycline, respectively. Thirteen (17.3%) strains were found to be PPNG and 15 (20%) were TRNG. Out of 24 penicillin-resistant strains, 13 (54.2%) were found to be PPNG and among the 23 tetracycline-resistant strains, 15 (65.2%) were found to be TRNG.
The MIC range, MIC 50 and MIC 90 of N. gonorrhoeae strains, to azithromycin were 0.016-0.25, 0.064 and 0.19 mg/mL, respectively [Table 2]. Cut-off MIC values that were used to determine susceptibility were as per CSLI guidelines  for all antimicrobial agents except azithromycin, for which CDC guidelines  were used. The acceptable linear correlation between MIC values of azithromycin with the inhibition zone diameter around azithromycin disc was achieved with a regression coefficient value ( r ) of -0.63 [Figure 1].
Out of 75 patients, only 42 who were treated with single oral dose of 2 g azithromycin were included in the analysis of clinical and microbiological outcome. All were male patients between 18 and 54 years age group. Only 22 (52.4%) patients out of 42 cases came for follow-up after 5-7 days. All the patients (100%) were cured clinically, i.e., completely became asymptomatic and showed excellent bacteriological response with direct microscopy and culture for N. gonorrhoeae becoming negative. The most common treatment-related side-effect was mild diarrhoea (8%) followed by mild abdominal pain (1.6%).
Increased resistance of N. gonorrhoeae isolates to oral fluoroquinolones has limited the options for effective treatment of gonorrhoea. Surveillance for antimicrobial resistance is crucial for monitoring the emergence and spread of antibiotic resistance in gonococcal isolates and to provide a rational basis for effective and affordable therapies for gonorrhoea. ,,
Although the cost of azithromycin and the frequency of gastrointestinal intolerance are higher than those of alternative therapies and are likely to limit routine use of this regimen, azithromycin has several potential advantages for treatment. First, it is highly effective in the treatment of gonorrhoea with a single oral dose. Second, it provides appropriate treatment when the cause of the urethritis/cervicitis is uncertain and when immediate therapy is required before the results of bacteriological or serological tests are available. Finally, mixed gonorrhoea and chlamydial infection can be treated with a single agent. ,,,
Adequate in vitro results have been generated to recommend a breakpoint MIC ( ≤1 mg/mL) and a correlate zone diameter ( ≥30 mm).  The results of some studies also have documented the clinical efficacy of a single oral dose of azithromycin (1 or 2 g) for treatment of gonorrhoea. ,,,
All gonococcal isolates were sensitive to azithromycin by the disc diffusion as well as E -test methods. Our study demonstrates the 100% clinical efficacy of single dose of 2 g azithromycin in the treatment of uncomplicated gonorrhoea in men and 100% correlation with the in vitro susceptibility results. Oral azithromycin may safely be recommended for treatment of uncomplicated gonorrhoea.
|1||Tapsall JW. Antibiotic resistance in Neisseria gonorrhoeae . Clin Infect Dis 2005; 41 :S263-8.|
|2||Dillon JA, Li H, Sealy J, Ruben M, Prabhakar P; Caribbean GASP Network. Gonococcal Antimicrobial Surveillance Program. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from three Caribbean countries: Trinidad, Guyana and St.Vincent. Sex Transm Dis 2001; 28 :508-14.|
|3||Ison CA, Dillon JA, Tapsall JW. The epidemiology of global antibiotic resistance among Neisseria gonorrhoeae and Haemophilus ducreyi . Lancet 1998; 351 :8-11.|
|4||Ison CA. Antimicrobial agents and gonorrhoea: Therapeutic choice, resistance and susceptibility testing. Genitourin Med 1996; 72 :253-7.|
|5||Gorwitz RJ, Nakashima AK, Moran JS, Knapp JS. Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae -United States, 1988-1991. MMWR CDC Surveill Summ 1993; 42 :29-39.|
|6||Rahman M, Alam A, Nessa K, Nahar S, Dutta DK, Yasmin L, et al . Treatment failure with the use of ciprofloxacin for gonorrhea correlates with the prevalence of fluoroquinolone-resistant Neisseria gonorrhoeae strains in Bangladesh. Clin Infect Dis 2001; 32 :884-9.|
|7||Bhalla P, Vidhani S, Reddy BS, Chowdhry S, Mathur MD. Rising quinolone resistance in Neisseria gonorrhoeae isolates from New Delhi. Indian J Med Res 2002; 115 :113-7.|
|8||Sethi S, Sharma D, Mehta SD, Singh B, Smriti M, Kumar B, Sharma M. Emergence of ciprofloxacin resistant Neisseria gonorrhoeae in north India. Indian J Med Res 2006; 123 :707-10.|
|9||Handsfield HH, McCormark WM, Hook EW 3rd, Douglas JM, Covino JM, Verdon MS, et al . A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. N Engl J Med 1991; 325 :1337-41.|
|10||Plourde PJ, Tyndall M, Agoki E, Ombette J, Slaney LA, D'Costa LJ, et al . Single-dose cefixime versus single-dose ceftriaxone in the treatment of antimicrobial-resistant Neisseria gonorrhoeae infection. J Infect Dis 1992; 166 :919-22.|
|11||Waugh MA. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhea in men and women. J Antimicrob Chemother 1993; 31 :193-8.|
|12||Mehaffeey PC, Putnam SD, Barrett MS, Jones RN. Evaluation of in vitro of activity of azithromycin, clarithromycin and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion and E-test methods. J Clin Microbiol 1996; 34 :479-81.|
|13||Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted disease. J Antimicrob Chemother 1990; 25 :109-14.|
|14||Steingrνmsson O, Olafsson JH, Thórarinsson H, Ryan RW, Johnson RB, Tilton RC. Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men. Sex Transm Dis 1994; 21 :43-6.|
|15||Handsfield HH, Dalu ZA, Martin DH, Douglas JM, McCarty JM, Schlossberg D. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis 1994; 21 :107-11.|
|16||Ballard RC, Ye H, Matta A, Dangor Y, Radebe F. Treatment of chancroid with azithromycin. Int J STD AIDS 1996; 7 :9-12.|
|17||Laboratory Diagnosis of Gonorrhoea. WHO Regional publication, South East Asia Series No.33. World Health Organization: Geneva; 1999.|
|18||Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 15 th informational supplement, M2-A8 and M7-A6. Vol. 25, Clinical and Laboratory Standards Institute 2005. p. 1.|
|19||Centers for Disease Control and Prevention. Disk Diffusion Susceptibility Testing: Neisseria gonorrhoeae reference strains for antimicrobial susceptibility testing. Neisseria Reference Laboratory ; Revised 2005.|
|20||Ye S, Su X, Wang Q, Yin Y, Dai X, Sun H. Surveillance of antibiotic resistance of Neisseria gonorrhoeae isolates in China, 1993-1998. Sex Transm Dis 2002; 29 :242-5.|